pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 29 Non-oncology: 19
Oncology: 10
Under Consideration for Negotiation 26 Non-oncology: 15
Oncology: 11
Completed Negotiations 678 With Letter of Intent: 581
Without agreement: 97
Negotiations That Were Not Pursued 101

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Omvoh Eli Lilly Canada Inc. Ulcerative Colitis
Lynparza AstraZeneca Canada Inc. Olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).
Koselugo Alexion Pharma GMBH For the treatment of pediatric patients aged 2 years and above, with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas
Onivyde Shire Pharma Canada ULC Metastatic Pancreatic Cancer
Pemazyre Incyte Biosciences Canada Corporation For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement and a ECOG performance status of 0 to 2,
Vyalev AbbVie Corporation For the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson's disease.
TheraSphere Y-90 Glass Micropheres Boston Scientific Corporation Hepatocellular carcinoma
SIR-Spheres Y-90 resin microspheres Sirtex Medical Hepatocellular carcinoma

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Poteligeo Kyowa Kirin Canada, Inc. mycosis fungoides (MF), Sézary syndrome (SS)
Imfinzi AstraZeneca Canada Inc. In combination with gemcitabine-based chemotherapy for the treatment of patients with locally advanced or metastatic biliary tract cancer (BTC)
Imfinzi and Imjudo ASTRAZENECA CANADA INC Imjudo (tremelimumab for injection) in combination with durvalumab is indicated for the first-line treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who require systemic therapy.

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
Ultomiris Alexion Pharma GMBH AChR antibody-positive generalized Myasthenia Gravis